Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Experience with tau-binding radiotracer [18F]T-807 accumulates

Jan. 27, 2014

Metformin treatment regimen active in refractory colorectal cancer

Jan. 23, 2014

OMP-59R5 proves active against metastatic pancreatic cancer

Jan. 23, 2014

Activity limited with trebananib plus sorafenib in hepatocellular carcinoma

Jan. 22, 2014

Phase II data show limited single-agent activity with ganetespib in metastatic pancreatic cancer

Jan. 22, 2014

New radioligands tested for assessment of AD in living subjects

Jan. 21, 2014

Preliminary trial results provided for selinexor in colorectal cancer

Jan. 21, 2014

Nektar Therapeutics reviews product development status for 2014

Jan. 21, 2014

Simtuzumab well tolerated in phase I and II trials

Jan. 21, 2014

Lanreotide autogel/depot reduces carcinoid syndrome rescue therapy in ELECT trial

Jan. 21, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
Gensci-134: a long-acting growth hormone receptor agonist fusion protein
BioWorld Science
Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone...